Clinical Trial

Continuous vs. Bolus Administration of NSAIDs After Laparoscopic Surgery for Multimodal Analgesia

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated July 17, 2025 (before its estimated May 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
Currently the prevalent approach to perioperative management of patients is ERAS (Enhanced Recovery After Surgery) concept. This approach includes numerous aspects, among which the perioperative use of multimodal analgesia takes one of the leading places. Within the ERAS guidelines all sorts of minimization of opioid analgesics use in schemes of postoperative analgesia are appreciated. Thus, new pharmacological approaches are being actively developed currently in order to achieve adequate analgesia and to minimize the use of this group of drugs. One of the most perspective trends within the multimodal analgesia concept is continuous infusion of non-steroidal anti-inflammatory drugs (NSAID). Up to date there are papers that both confirm the effectiveness of this method for maintaining adequate postoperative analgesia and show its limitations and deny the advantages of the continuous use of NSAID. Up to this time the main attention of the medical community was paid for such drugs as paracetamol and ketoprofen. Nevertheless, one of the most common and safe NSAID is ibuprofen. In spite of this, there are no studies that explore the effectiveness of the continuous infusion of this drug. Thus, the lack of even low-quality evidence led to setting up a study of effectiveness and safety of continuous infusion of ibuprofen in comparison to its bolus injection.
Trial Details
NCT Number NCT07070050
Lead Sponsor Federal Research and Clinical Centre of Intensive Care Medicine and Rehabilitology
Conditions Analgesic Drugs, Analgesic, Nonopioid, Analgesic Efficacy, Analgetic Consumption, Postoperative Care, Pain Management
Enrollment 100 participants
Start Date 2025-05-05
Primary Completion 2026-05-20 (estimated)
Study Completion 2026-11-20 (estimated)
Updated on ClinicalTrials.gov 2025-07-17